Syngene International Ltd.

673.00 -5.70 ▼-0.8%

06 May 2024, 04:01:00 PM
Volume: 8,510

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.syngeneintl.com
Market Cap 27,118.92 Cr.
Enterprise Value(EV) 26,697.12 Cr. 2024-03
Financial Indicators
Earnings per share (EPS) 12.67 Trailing Twelve Months Ending 2024-03
Price-Earning Ratio (PE) 53.17 Trailing Twelve Months Ending 2024-03
Industry PE 42.26 Trailing Twelve Months Ending 2024-03
Book Value / Share 105.79 Trailing Twelve Months Ending 2024-03
Price to Book Value 6.37 Calculated using Price: 673.70
Dividend Yield 0.19 Period Ending 2023-03
No. of Shares Subscribed 40.25 Cr. 402,536,981 Shares
FaceValue 10
About Syngene International Ltd.
The company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Services offered by the company are Discovery Chemistry, Discovery Biology, Safety Assessment, Large Molecule Development, Chemical Development, Formulation Development, Stability Studies, Polymer Research, Integrated Discovery & Development, Clinical Development Services, Bioinformatics, Antibody Drug Conjugates, Oligonucleotide Synthesis.

Syngene International Ltd. Delivery

Delivered Qty
Traded Qty

Syngene International Ltd. Performance

1 Day
-0.84%
1 Week
-3.62%
1 Month
-6.57%
3 Month
-9.45%
6 Month
-2.78%
1 Year
-2.36%
2 Year
+8.65%
5 Year
+124.17%
10 Year

Syngene International Ltd. Fundamental Ratios

6 years 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 18.05 18.26 20.21 16.59 13.29 13.73
Return on Capital Employed (%) 15.76 16.98 19.6 15.4 13.24 15.43
Return on Assets (%) 9.8 9.86 10.77 9.17 7.69 8.25

Syngene International Ltd. Balance Sheet

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2024-03* Rs. Cr.
Shh. Funds 1,720 1,968 2,176 2,821 3,298 3,618 4,258
Non Curr. Liab. 613 515 325 840 972 955 709
Curr. Liab. 784 1,129 1,539 1,133 1,229 1,188 1,144
Minority Int.
Equity & Liab. 3,117 3,612 4,040 4,794 5,498 5,761 6,111
Non Curr. Assets 1,396 1,848 2,428 2,987 3,292 3,336 4,152
Curr. Assets 1,720 1,764 1,613 1,807 2,206 2,425 1,959
Misc. Exp. not W/O
Total Assets 3,117 3,612 4,040 4,794 5,498 5,761 6,111

Syngene International Ltd. Profit and Loss

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2024-03 Rs. Cr. TTM
Net Sales 1,423 1,826 2,012 2,184 2,604 3,193 3,489
Other Income 136 76 96 83 108 73 91
Total Income 1,559 1,902 2,108 2,268 2,713 3,266 3,579
Total Expenditure -1,033 -1,290 -1,409 -1,531 -1,864 -2,260 -2,474
PBIDT 527 612 700 736 849 1,005 1,105
Interest -23 -32 -35 -28 -24 -45 -47
Depreciation -131 -164 -219 -275 -310 -367 -426
Taxation -67 -84 -105 -64 -89 -129 -111
Exceptional Items 71 35 -31 -11
PAT 305 332 412 405 396 464 510
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 305 332 412 405 396 464 510
Adjusted EPS 8 8 10 10 10 12 13

Syngene International Ltd. Cash Flow

Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 446 630 677 701 581 824
Cash Fr. Inv. -349 -647 -428 -628 -612 -656
Cash Fr. Finan. -79 -72 -226 58 -31 -343
Net Change 18 -89 23 131 -62 -175
Cash & Cash Eqvt 253 165 193 323 262 90

Syngene International Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 70.41 70.29 64.86 64.86 54.88 54.80 54.79 54.79 54.79
Public 29.59 29.71 35.14 35.14 45.12 45.20 45.20 45.21 45.21
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Syngene International Ltd. Announcements

Mon, 29 Apr 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) please find the link for the transcript of the Q4 FY24 Earnings Call conducted on April 25 2024 and uploaded on the website of the Company on April 29 2024.
Sun, 28 Apr 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Intimation regarding submission of appeal to the National Faceless Appeal Centre against Order under Section 143(3) read with Section 144B of the Income Tax Act 1961
Fri, 26 Apr 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication - Financial results.

Syngene International Ltd. Technical Scans

Mon, 06 May 2024
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease in 1 Month High Decrease in 1 Month
High Decrease in 3 Months High Decrease in 3 Months
High Increase in 5 Years High Increase in 5 Years
MFI Crossed 20 From Above MFI Crossed 20 From Above

Syngene International Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 367,026.27 1,529.55 +1.4%
Cipla Ltd. 114,924.60 1,423.40 -0.1%
Divi's Laboratories Ltd. 105,128.21 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. 105,108.85 6,293.45 -0.9%
Zydus Lifesciences Ltd. 102,736.49 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. 91,906.55 2,720.45 -0.4%
Mankind Pharma Ltd. 91,490.39 2,286.05 -1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.21 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 30.99 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 76.02 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.10 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.55 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 61.52 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 52.97 2,286.05 -1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.88 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-12 4.44 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 8.07 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.91 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.45 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-12 10.30 2,286.05 -1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 0.02 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 12.85 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,286.05 -1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,286.05 -1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,529.55 +1.4%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,423.40 -0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,958.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,293.45 -0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,020.75 +2.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,720.45 -0.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,286.05 -1.2%

Syngene International Ltd. FAQ's

What is Syngene Internation. share price?

Can I buy Syngene Internation. shares now?

What is the Dividend Yield of Syngene Internation.?

What is the Market Cap of Syngene Internation.?

What are the key metrics to analyse Syngene Internation.?

What is the 52 Week High and Low of Syngene Internation.?

What is the trend of Syngene Internation. share price?